Panel Discussion | Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs
Evaluating Triple Therapy Treatment Pathways in Chronic Obstructive Pulmonary Disease (COPD): A Machine-Learning Predictive Model
GNS and Arvinas Enter into Neuroscience Drug Discovery Collaboration
GNS and the Global Alzheimer’s Platform Foundation® Partner to Advance Alzheimer’s R&D
GNS Appoints John Maraganore, PhD, as Strategic Advisor
BioWorld | BIO 2022: Push to model disease biology advancing, but slowly
ASCO | PTCH1 and AXIN2 modulation of AR copy number effects on AR gene overexpression in metastatic castration resistant prostate cancer (mCRPC).
The case for AI-driven cancer clinical trials –
The efficacy arm in silico
Read more →
GNS Healthcare Announces a Multi-Year Collaboration with Memorial Sloan Kettering’s Innovation Hub to Advance Precision Medicine in Oncology
Read more →
GNS to Develop the World’s First in silico Patient For Prostate Cancer
Read more →
Listen to Dr. Ravi Parikh talk about the challenges of RCT and the GNS in silico Patient solutions
Listen to more →
At GNS, we reveal the hidden biological circuitry of disease to create the world’s most accurate digital twins. These digital twins are powered by the recent explosive growth of multi-omic and clinical patient data and our patented Causal AI and Simulation technology REFS™.
Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across “digital twins cohorts” to discover and validate novel drug targets.
Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across “digital twins cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.
Gemini – Digital Twin is fueled by integrated multi-omic and clinical patient data in specific diseases from a rapidly growing array of world class partners and the patented causal AI and simulation technology, REFS™. These “digital twins” link patient characteristics to drug treatments to the “revealed” complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the world’s most accurate simulation of disease progression and drug response at an individual patient level across “digital twins cohorts.” Gemini Digital Twins have been launched in multiple myeloma, prostate cancer, Alzheimer, and Parkinson’s, with several more in development.